Gilder Gagnon Howe & Co. LLC decreased its position in shares of DexCom Inc. (NASDAQ:DXCM) by 11.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 698,642 shares of the medical device company’s stock after selling 87,405 shares during the period. Gilder Gagnon Howe & Co. LLC owned 0.83% of DexCom worth $61,243,000 as of its most recent filing with the SEC.
Several other large investors also recently modified their holdings of the stock. BNP Paribas Arbitrage SA raised its stake in shares of DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock worth $105,000 after buying an additional 1,162 shares during the period. Bellwether Investment Group LLC bought a new stake in shares of DexCom during the second quarter worth about $119,000. Capstone Asset Management Co. bought a new stake in shares of DexCom during the third quarter worth about $205,000. ProShare Advisors LLC bought a new stake in shares of DexCom during the second quarter worth about $219,000. Finally, Private Bank & Trust Co. bought a new stake in shares of DexCom during the third quarter worth about $220,000.
DexCom Inc. (NASDAQ:DXCM) opened at 84.16 on Thursday. DexCom Inc. has a 12-month low of $47.92 and a 12-month high of $96.38. The company’s market cap is $7.11 billion. The stock’s 50 day moving average is $65.50 and its 200 day moving average is $79.15.
DXCM has been the topic of a number of recent research reports. B. Riley initiated coverage on shares of DexCom in a report on Monday, September 26th. They set a “neutral” rating and a $97.00 price target on the stock. Zacks Investment Research downgraded shares of DexCom from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 4th. BTIG Research upgraded shares of DexCom from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a report on Monday, October 31st. Wedbush restated an “outperform” rating and set a $112.00 price target (up previously from $100.00) on shares of DexCom in a report on Wednesday, November 2nd. Finally, Canaccord Genuity cut their price target on shares of DexCom from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Wednesday, November 2nd. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. DexCom currently has an average rating of “Buy” and an average price target of $89.60.
In other DexCom news, EVP Andrew K. Balo sold 3,200 shares of the stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $62.86, for a total value of $201,152.00. Following the completion of the sale, the executive vice president now owns 109,545 shares in the company, valued at $6,885,998.70. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Richard Doubleday sold 3,182 shares of the stock in a transaction on Friday, December 23rd. The shares were sold at an average price of $62.17, for a total transaction of $197,824.94. Following the completion of the sale, the executive vice president now owns 83,582 shares of the company’s stock, valued at approximately $5,196,292.94. The disclosure for this sale can be found here. Corporate insiders own 2.80% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom Inc. (NASDAQ:DXCM).